MedPage Today on MSN
FDA calls for testing before treatment with widely used chemotherapies
Notice highlights risks of DPD deficiency with capecitabine, fluorouracil ...
The labeling updates address the risk of early-onset toxicity, including life-threatening adverse events in patients with DPD ...
Complete DPD deficiency markedly impairs 5-FU catabolism, increasing risk of early severe diarrhea, mucositis, neutropenia, ...
Sept. 8, 2004 — The U.S. Food and Drug Administration (FDA) approved in June revisions to safety labeling to advise healthcare professionals of the following changes: estradiol/norethindrone patches ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results